drugset

drugset / Trial / NCT02527785

Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer

NCT02527785 ↗

Phase 2 Completed 44 enrolled Hallym University Medical Center Jeil Pharmaceutical Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

This study will conduct a phase II study of triple combination with oxaliplatin, irinotecan, and S-1 as the first-line chemotherapy in patients with advanced gastric cancer.

Timeline

Start: 2015-02
Primary completion: 2016-06
Completion: 2017-04

Publications

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	135 mg/m2	Intravenous
Subject	Oxaliplatin	Small molecule	65 mg/m2	Intravenous
Subject	S-1	Small molecule	80 mg/m2	Oral

Indications